Q-omics provides the consensus-scored DENND4B profile across patient tissues and cancer cell-line models. DENND4B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DENND4B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, DENND4B protein abundance shows 22,503 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where DENND4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND4B survival associations across molecular data types. DENND4B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND4B RNA expression–survival associations across cancer types. High DENND4B expression shows unfavorable associations in KIRP, ACC, KIRC, LIHC and KICH, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DENND4B RNA expression.
This table summarizes DENND4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DENND4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND4B shows higher tumor expression in KIRC, COAD, HNSC, LIHC, STAD and KIRP. The KIRC box plot shows higher DENND4B RNA expression in tumor versus normal tissue (log2 FC = +0.624, t-test p < 0.001).
This table shows molecular features associated with DENND4B in patient tissues and cancer cell lines. In patient samples, DENND4B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
